Supranuclear palsy – Diagnostics – Overview of Information and Clinical Research

Diagnosing progressive supranuclear palsy requires careful observation and specialized testing, as this rare brain condition often mimics other diseases and can take time to identify accurately.

Introduction: Who Should Seek Diagnostic Testing

Progressive supranuclear palsy, often called PSP, is a rare brain disorder that can be challenging to diagnose, especially in its early stages. If you or someone you care about experiences unexplained falls, particularly falling backward, along with difficulty looking up or down with the eyes, it may be time to seek medical evaluation. These symptoms can appear suddenly and worsen over time, which is why early assessment becomes important.^[1]

People who should consider seeking diagnostic testing include those experiencing a combination of balance problems, frequent falls, changes in eye movement, stiffness in the body, slowed movements, or changes in thinking and behavior. The condition most commonly affects people over the age of 60, though it can occasionally begin in the 40s or 50s.^[2]^[7]

It is especially important to seek evaluation from a doctor if standard treatments for Parkinson’s disease are not working, or if symptoms progress faster than expected. More than half of people with PSP are initially misdiagnosed with Parkinson’s disease because the two conditions share similar symptoms. However, PSP progresses more rapidly and has distinct features that help doctors tell them apart.^[7]^[16]

⚠️ Important

The diagnosis must be made or confirmed by a consultant with expertise in PSP, usually a neurologist who specializes in conditions affecting the brain and nerves. Because PSP is rare and unfamiliar to many healthcare providers, the diagnostic process can be lengthy and frustrating. Even for those not initially misdiagnosed, receiving an accurate diagnosis can take considerable time.^[5]^[7]

Consulting a movement disorder specialist becomes crucial when symptoms are puzzling or when initial treatments fail to bring relief. Healthcare professionals usually begin to rethink the diagnosis when symptoms progress faster than expected with Parkinson’s disease, or when typical medications for Parkinson’s do not provide improvement.^[7]

Classic Diagnostic Methods

There is currently no single test that can diagnose progressive supranuclear palsy with certainty. Instead, doctors rely on a careful pattern of symptoms, medical history, physical examination, and imaging tests to reach a diagnosis. The process involves ruling out other conditions that can cause similar symptoms, which is why it can take time to arrive at the correct answer.^[5]^[7]

Clinical Evaluation and Symptom Pattern

The foundation of PSP diagnosis is the clinical evaluation performed by a neurologist. This involves a detailed discussion about the symptoms you are experiencing, when they started, and how they have changed over time. The doctor will ask about falls, eye movement difficulties, changes in speech or swallowing, and any mood or thinking changes.^[8]

During the physical examination, the neurologist will carefully assess your movements, balance, muscle stiffness, and eye movements. A key feature that helps doctors suspect PSP rather than Parkinson’s disease is the pattern of symptoms. People with PSP typically do not have tremors, which are common in Parkinson’s disease. They tend to have many unexplained falls, especially falling backward. They also commonly have trouble moving their eyes, particularly looking downward, which is less common in Parkinson’s disease.^[6]^[8]

Another important clue is how the body responds to medications used for Parkinson’s disease. People with PSP typically have little, temporary, or no response to these medicines, while people with Parkinson’s disease usually experience significant improvement. This response to treatment, or lack of it, can serve as a diagnostic test to help eliminate the possibility of Parkinson’s disease.^[8]^[15]

Brain Imaging Studies

Magnetic resonance imaging (MRI) is a crucial diagnostic tool for PSP. An MRI uses magnets and radio waves to create detailed pictures of the brain. In people with PSP, the MRI may show shrinkage in specific regions of the brain, particularly in the midbrain area. This pattern of brain changes can help distinguish PSP from other conditions.^[8]^[21]

One characteristic finding on MRI is called the “hummingbird sign” or “penguin silhouette sign.” This refers to the appearance of the midbrain, which looks like the body and head of a hummingbird when viewed from the side. The midbrain shows atrophy, meaning it has become smaller due to the deterioration of brain cells. This visual clue helps neurologists confirm their suspicion of PSP.^[3]

The MRI also helps exclude other disorders that may mimic PSP, such as stroke, tumors, or other brain conditions. By ruling out these other possibilities, doctors can be more confident in a PSP diagnosis.^[8]

A positron emission tomography (PET) scan may also be recommended in some cases. This imaging test can detect early signs of changes in the brain that may not yet appear on an MRI. PET scans measure brain activity and can show areas where cells are not functioning normally. This can be particularly helpful in the early stages of the disease when MRI changes may still be subtle.^[8]^[21]

Specialized Eye Movement Testing

Because eye movement problems are a hallmark of PSP, specialized testing of eye movements can be very helpful in diagnosis. A neuro-ophthalmologist or ophthalmologist may evaluate how well you can move your eyes in different directions, especially up and down. They will assess whether you have slow eye movements, trouble looking up or down, difficulty controlling eyelids, or decreased blinking.^[4]^[6]

The term “supranuclear” in the disease name refers to the area of the brain affected, which is above the eye-moving centers in the brain. This leads to a characteristic pattern where voluntary eye movements become limited, but reflexes that control the eyes remain preserved. This distinction helps doctors identify PSP.^[2]

Differential Diagnosis

An important part of diagnosing PSP is distinguishing it from other similar conditions. PSP can be mistaken for Parkinson’s disease, Alzheimer’s disease, corticobasal degeneration, multiple system atrophy, or frontotemporal dementia. All of these conditions can share some overlapping symptoms, making diagnosis challenging.^[3]^[4]

Several key differences help doctors tell PSP apart from Parkinson’s disease. People with PSP tend to lean backward and extend their neck, while people with Parkinson’s tend to bend forward. Falls in PSP usually happen from falling backward, whereas in Parkinson’s, people tend to fall forward. Tremor is characteristic in Parkinson’s but uncommon in PSP. Additionally, PSP progresses more rapidly than Parkinson’s disease, with most people developing severe disability within three to five years of symptom onset.^[6]^[14]

Tests of Memory and Thinking

As PSP can affect cognitive abilities, doctors may conduct tests to assess memory, concentration, and the ability to understand language. These neuropsychological tests help evaluate thinking skills and can reveal changes in behavior, judgment, problem-solving, and word-finding abilities that are common in PSP.^[5]

People with PSP may experience slowed thinking, forgetfulness, difficulty making decisions, impaired abstract thought, and sometimes a lack of inhibition. These cognitive changes can develop early in the disease or appear later as the condition progresses.^[4]^[6]

Additional Testing

In some cases, doctors may order blood tests or other laboratory studies to rule out other conditions that could cause similar symptoms. There are no specific blood tests that diagnose PSP, but testing can help exclude other medical problems such as thyroid disorders, vitamin deficiencies, or infections that might affect brain function.^[5]

Diagnostics for Clinical Trial Qualification

For people interested in participating in clinical trials for PSP, additional diagnostic testing may be required beyond what is used for standard clinical diagnosis. Clinical trials are research studies that test new treatments or therapies, and they have specific criteria that participants must meet to be eligible.^[12]

To qualify for a clinical trial, participants typically need a confirmed diagnosis of PSP made by a movement disorder specialist or neurologist experienced with the condition. The diagnosis must often meet specific diagnostic criteria established by research organizations. These criteria define the symptoms and test results that must be present for someone to be included in the trial.^[12]

Imaging studies such as MRI or PET scans are commonly required as part of the screening process for clinical trials. These scans help researchers confirm that brain changes consistent with PSP are present and may also establish a baseline against which to measure any changes during the trial. Some trials may use advanced imaging techniques to measure specific areas of brain atrophy or to detect the accumulation of tau protein, which is the abnormal protein that builds up in the brains of people with PSP.^[4]^[12]

Comprehensive neurological examinations and cognitive testing are standard requirements for trial enrollment. Researchers need to document the severity of symptoms at the beginning of the trial so they can measure whether the experimental treatment has any effect. This may include detailed assessments of walking ability, balance, eye movements, speech, swallowing, and cognitive function.^[12]

Some clinical trials are testing drugs that work in different ways, and researchers are using innovative approaches to evaluate multiple treatments at the same time. For example, a major clinical trial funded by the National Institutes of Health is testing three drugs concurrently at up to 50 sites nationwide. This type of trial allows researchers to find effective therapies more quickly than testing one drug at a time.^[12]

Blood tests or other laboratory work may also be part of trial screening to ensure that participants are healthy enough to receive the experimental treatment and to rule out other medical conditions that might interfere with the study results. Participants may need to meet certain age requirements, disease duration criteria, or functional ability standards to be eligible.^[12]

It is important to understand that participation in a clinical trial is voluntary, and there is no guarantee that the experimental treatment will be effective. However, trials offer hope for developing new therapies and contributing to scientific knowledge that may help future patients. If you are interested in clinical trials for PSP, talk to your neurologist or visit clinical trial registries to learn about available studies.^[12]

Prognosis and Survival Rate

Prognosis

Progressive supranuclear palsy is a condition that worsens over time and cannot be cured. The disease progresses at different rates in different people, but generally moves more rapidly than Parkinson’s disease. Most people with PSP develop severe disability within three to five years of when symptoms first appear.^[6]^[14]

As the disease progresses, people with PSP experience increasing difficulties with balance and walking, leading to more frequent falls. Eye movement problems become more pronounced, making it harder to read, navigate stairs, and maintain eye contact during conversations. Speech and swallowing difficulties worsen, which can lead to serious complications such as choking or aspiration pneumonia, a lung infection caused by food or liquid entering the airways.^[1]^[6]

The disease also affects thinking and behavior more significantly over time. People may experience increasing cognitive impairment, mood changes, and personality changes. These changes can make daily activities increasingly difficult and affect quality of life for both the person with PSP and their caregivers.^[6]

Complications from PSP can be serious. Pneumonia is a leading cause of death in people with PSP, often resulting from swallowing difficulties that allow food or liquid to enter the lungs. Choking is another serious risk. Head injuries from falls can also lead to dangerous complications. For these reasons, careful management and supportive care become increasingly important as the disease progresses.^[6]^[14]

There is currently no treatment that can stop the progression of PSP. However, good care and assistance can help someone with PSP maintain better independence and quality of life for as long as possible. Treatment focuses on managing symptoms and preventing complications through supportive therapies such as physical therapy, occupational therapy, and speech therapy.^[5]

Survival Rate

Progressive supranuclear palsy shortens life expectancy. The usual survival time after diagnosis is typically between seven and ten years, though this can vary from person to person. Some people may live longer, while others may have a shorter course of disease.^[12]^[19]

The Richardson syndrome subtype, which is the most common form of PSP, tends to progress relatively quickly. Patients with this form often have a shortened survival rate compared to the general population. The rate of progression and survival can depend on several factors, including the specific symptoms present, the person’s overall health, and how well complications are managed.^[4]

It is important to note that while these statistics provide general guidance, each person’s experience with PSP is unique. Some individuals may progress more slowly than others, and advances in supportive care continue to improve quality of life for people living with this condition.^[4]

#1 Clinical Trials Search in Europe